Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TScan Therapeutics, Inc. (TCRX : NSDQ)

• Company Description    TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass. Number of Employees: 194

• Price / Volume Information    Yesterday's Closing Price: $1.76 Daily Weekly Monthly 20 Day Moving Average: 204,114 shares Shares Outstanding: 56.75 (millions) Market Capitalization: $99.88 (millions) Beta: 1.00 52 Week High: $6.23 52 Week Low: $1.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.76% -4.47% 12 Week 20.55% 9.50% Year To Date -42.11% -45.67%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 830 WINTER STREET - WALTHAM,MA 02451 USA ph: 857-399-9500 fax: - hsavelle@tscan.com http://www.tscan.com

• General Corporate Information    Officers Gavin MacBeath - Chief Executive Officer and Director Jason A. Amello - Chief Financial Officer Garry Nicholson - Director Stephen Biggar - Director Katina Dorton - Director Peer Information TScan Therapeutics, Inc. (CORR.) TScan Therapeutics, Inc. (RSPI) TScan Therapeutics, Inc. (CGXP) TScan Therapeutics, Inc. (BGEN) TScan Therapeutics, Inc. (GTBP) TScan Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89854M101 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 56.75 Most Recent Split Date: (:1) Beta: 1.00 Market Capitalization: $99.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.57 Price/Cash Flow: - Price / Sales: 14.35 EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -7.69% Sales Growth vs. Year Ago Period: 473.88% vs. Previous Quarter: 41.69% ROE 06/30/25 - -63.33 03/31/25 - -55.76 12/31/24 - -59.61 ROA 06/30/25 - -40.19 03/31/25 - -36.56 12/31/24 - -37.88 Current Ratio 06/30/25 - 7.06 03/31/25 - 8.55 12/31/24 - 8.14 Quick Ratio 06/30/25 - 7.06 03/31/25 - 8.55 12/31/24 - 8.14 Operating Margin 06/30/25 - -1,949.22 03/31/25 - -2,949.42 12/31/24 - -4,488.96 Net Margin 06/30/25 - -1,964.88 03/31/25 - -2,974.08 12/31/24 - -4,527.66 Pre-Tax Margin 06/30/25 - -1,964.88 03/31/25 - -2,974.08 12/31/24 - -4,527.66 Book Value 06/30/25 - 3.11 03/31/25 - 3.71 12/31/24 - 4.26 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.18 03/31/25 - 0.15 12/31/24 - 0.13 Debt-to-Capital 06/30/25 - 15.45 03/31/25 - 13.28 12/31/24 - 11.75

Powered by Zacks Investment Research ©